Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Immunodiagnostic Systems Holdings Plc LSE:IDH London Ordinary Share GB00B01YZ052 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -10.00p -5.00% 190.00p 180.00p 200.00p 200.00p 190.00p 200.00p 14,486 08:03:19
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 37.9 0.9 4.2 45.2 54.69

Immunodiagnostic Systems Share Discussion Threads

Showing 651 to 675 of 900 messages
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
DateSubjectAuthorDiscuss
28/6/2011
14:38
Have seen Brewin Note. Price target upped to 1230p from 1195p, Conviction Buy.
philo124
28/6/2011
07:54
Rodozz,my decision was a decision, not an idea.
philo124
28/6/2011
00:03
Philo124 hope your decision to sell FPM and buy XEL is sitting well with you. Next time maybe keep your ideas to yourself ?
rodozz
27/6/2011
22:42
Thanks; in ODX as well.
philo124
27/6/2011
22:40
Agree with Phil -- this company look to have many things going for it -- attacive market place, high margins, competent board etc
campbed
27/6/2011
22:36
Great Results!
philo124
04/6/2011
19:19
£12, short term target for this month run up to the results ?
spacecake
01/6/2011
10:54
Nearly at £10; my target £12. fwiw.
philo124
05/5/2011
19:10
GOOD rise today.
philo124
13/4/2011
15:31
http://www.growthcompany.co.uk/recommendations/1618118/immunodiagnostic-systems-holdings.thtml Market maven Ben Jaglom on Immunodiagnostic
rumithepoet
06/4/2011
08:26
good update imo. I sold out around the japan crisis. This will make me re-think Immunodiagnostic Systems Holdings plc Trading Update Immunodiagnostic Systems Holdings plc ("IDS" or "the Company"), a leading producer of specialist diagnostic testing kits for the clinical and research markets, provides a trading update for the financial year ending 31 March 2011. Turnover for the year ending 31 March 2011 is expected to be £50.1m, circa 35% ahead of last year's performance (FY10: £37.2m) with trading in all of the Company's main territories having increased year on year. Sales of both manual vitamin D and automated products have increased compared to last year. Revenues from our manual Vitamin D kits increased by 27% to £27.9m compared to same period last year (FY10: £22m). We are also pleased to report that sales and placements of the IDS-iSYS system have continued to increase and in the second half of the year, as we have sold and or placed another 101 instruments bringing the total number post launch to 241. Number of IDS-iSYS instruments sold and placed post launch: Accounting Period Reagent Rentals Distribution Sales OEM & Partners Total cumulative cumulative cumulative cumulative Comparative H1 12 5 10 27 Comparative H2 31 19 24 74 Current year H1 62 28 50 140 Current year H2 113 46 82 241 Average revenue per instrument from our own reagent rental accounts was ahead of management expectations at £102,000, circa 32% ahead of last year's performance (FY10: £77,000). IDS-iSYS revenues accounted for circa 21% of total turnover, with sales in H2 of £7.0m compared to £3.3m in H1. Comparative sales in the previous year were H2: £2.1m and H1 £0.6m. During the period the Company signed an exclusive Agreement with Omega Diagnostics Group PLC giving them the exclusive rights to develop and distribute their range of allergy products on the IDS-iSYS. In return IDS receives a licence fee, a royalty on Omega automated product sales and revenues from both instrument and consumable sales. Balance Sheet The Company has been asked to consider a renegotiation of the timing of payment of the deferred consideration receivable (€3.4m) in respect of the disposal in December 2008 of its Haematology Division. As of today's date there has been no provision made against this amount in the Company's Accounts. The position is being reviewed by the Board in light of this request. Outlook We look forward to reporting our results for the financial year ended 31 March 2011 on Monday 27 June 2011 and continue to look forward to the current year with confidence.
dasv
06/4/2011
08:04
With Mkt Cap of 240m and Profit growth i don't think it's material and neither should the market.
philo124
06/4/2011
07:52
How do you think the market will react to the news that deferred consideration payment may not be forthcoming?
alter ego
06/4/2011
07:42
Great! I am going for historic 48p eps, up 60% on last year. Previously set a price target of £12.
philo124
06/4/2011
07:32
trading update www.investegate.co.uk/Article.aspx?id=201104060700053626E
alter ego
31/3/2011
07:49
Useful RNS.
philo124
28/3/2011
08:48
David Evans is non exec Chairman of Omega
silverfern
12/3/2011
18:31
There was 150,000 sell at 730p friday am.
philo124
11/3/2011
13:48
Seems to have no buying interest, directors selling, no news flow.
spacecake
11/3/2011
12:42
this looks bad, no news? any ideas anyone?
jpcarvil
24/2/2011
14:46
Great, thanks a lot! My target £12 Also GB Group 48p target which i hold so that was useful to know too!
philo124
24/2/2011
14:35
http://www.my-share.co.uk/Broker-notes-February-2011/broker-notes-february-2011.html Broker upgrade
nellie1973
23/2/2011
12:28
Chunky trades again. Looked at historic RNS's- not due for any more until mid April.
philo124
06/2/2011
08:59
I still maintain my £12 target despite all the rumours that have been flying around in the last 6 weeks.
philo124
06/2/2011
08:54
Do we have a triple head and shoulders that would indicate a fall in the SP?
chfrank
Chat Pages: 36  35  34  33  32  31  30  29  28  27  26  25  Older
Your Recent History
LSE
IDH
Immunodiag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20190619 11:00:38